These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 17466958

  • 1. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat.
    Blaauw Y, Schotten U, van Hunnik A, Neuberger HR, Allessie MA.
    Cardiovasc Res; 2007 Jul 01; 75(1):89-98. PubMed ID: 17466958
    [Abstract] [Full Text] [Related]

  • 2. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
    Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA.
    Circulation; 2004 Sep 28; 110(13):1717-24. PubMed ID: 15364815
    [Abstract] [Full Text] [Related]

  • 3. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
    de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, Allessie M, Schotten U.
    Circulation; 2006 Sep 19; 114(12):1234-42. PubMed ID: 16940189
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of pharmacologic cardioversion of atrial fibrillation by Class I drugs.
    Allessie MA, Wijffels MC, Dorland R.
    J Cardiovasc Electrophysiol; 1998 Aug 19; 9(8 Suppl):S69-77. PubMed ID: 9727679
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.
    Duytschaever M, Blaauw Y, Allessie M.
    Cardiovasc Res; 2005 Jul 01; 67(1):69-76. PubMed ID: 15949471
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.
    Eijsbouts S, Ausma J, Blaauw Y, Schotten U, Duytschaever M, Allessie MA.
    J Cardiovasc Electrophysiol; 2006 Jun 01; 17(6):648-54. PubMed ID: 16836716
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Exaggerated QT prolongation after cardioversion of atrial fibrillation.
    Choy AM, Darbar D, Dell'Orto S, Roden DM.
    J Am Coll Cardiol; 1999 Aug 01; 34(2):396-401. PubMed ID: 10440151
    [Abstract] [Full Text] [Related]

  • 12. Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.
    van Hunnik A, Lau DH, Zeemering S, Kuiper M, Verheule S, Schotten U.
    Heart Rhythm; 2016 Apr 01; 13(4):964-72. PubMed ID: 26681610
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation.
    Kalifa J, Bernard M, Gout B, Bril A, Cozma D, Laurent P, Chalvidan T, Deharo JC, Djiane P, Cozzone P, Maixent JM.
    Cardiovasc Drugs Ther; 2007 Feb 01; 21(1):47-53. PubMed ID: 17356910
    [Abstract] [Full Text] [Related]

  • 15. Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation.
    Huang HD, Waks JW, Steinhaus DA, Zimetbaum P.
    Heart Rhythm; 2016 Jul 01; 13(7):1410-7. PubMed ID: 26921760
    [Abstract] [Full Text] [Related]

  • 16. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
    Hongo RH, Themistoclakis S, Raviele A, Bonso A, Rossillo A, Glatter KA, Yang Y, Scheinman MM.
    J Am Coll Cardiol; 2004 Aug 18; 44(4):864-8. PubMed ID: 15312873
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
    Yamamoto W, Hashimoto N, Matsuura J, Machida T, Ogino Y, Kobayashi T, Yamanaka Y, Ishiwata N, Yamashita T, Tanimoto K, Miyoshi S, Fukuda K, Nakaya H, Ogawa S.
    J Cardiovasc Pharmacol; 2014 May 18; 63(5):421-7. PubMed ID: 24805146
    [Abstract] [Full Text] [Related]

  • 19. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G, Xue X, Gao C, Huang J, Qi D, Zhang Y, Dong JZ, Ma CS, Yan GX.
    J Am Heart Assoc; 2017 May 18; 6(5):. PubMed ID: 28522677
    [Abstract] [Full Text] [Related]

  • 20. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol.
    Wijffels MC, Dorland R, Mast F, Allessie MA.
    Circulation; 2000 Jul 11; 102(2):260-7. PubMed ID: 10889140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.